The background to finerenone and the FIDELIO CKD trial was covered in a post on the 11th of July.
Last week, there was a coordinated presentation at the American Society of Nephrology Kidney Week and a publication in the New England Journal of Medicine of the details of the the FIDELIO CKD.
In a nutshell, the main finding is a 18% reduction in the Primary Kidney Composite Endpoint in the Finerenone group versus the Placebo group (p = 0.0014).Numbers Needed to Treat (NNT) for Primary and Secondary endpoints over 3 years are 29 and 42. The serum potassium increased by a mere 0.2 mmol/l in the finerenone group and there was no increase incidence of AKI.
If you want to watch the High Impact Clinical Trial presentation at Kidney Week 2020 Reimagined, it’s the first item in the video. EMPEROR REDUCED and DAPA CKD are the second and last items respectively.
If you are too busy to watch, here are the salient slides: